Combination Treatment with Hepatitis C Virus Protease and NS5A Inhibitors Is Effective against Recombinant Genotype 1a, 2a, and 3a Viruses

With the development of directly acting antivirals, hepatitis C virus (HCV) therapy entered a new era. However, rapid selection of resistance mutations necessitates combination therapy. To study combination therapy in infectious culture systems, we aimed at developing HCV semi-full-length (semi-FL)...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gottwein, Judith M., Jensen, Sanne B., Li, Yi-Ping, Ghanem, Lubna, Scheel, Troels K. H., Serre, Stéphanie B. N., Mikkelsen, Lotte, Bukh, Jens
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2013
Témata:
Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3591891/
https://ncbi.nlm.nih.gov/pubmed/23274664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02164-12
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky